Figure 5.

Peptide-specific CTL induction using survivin-2B80-88 peptide and survivin-C58 peptide from PBMCs of HLA-A*2402⁺ oral cancer patients. PBMCs of HLA-A*2402⁺ oral cancer patients were stimulated in vitro with survivin-2B80-88 peptide-pulsed APCs (APC+2B80-88) and survivin-C58 peptide-pulsed APCs (APC+C58) separately, followed by assessment of the peptide-specific cytotoxic activity by ⁵¹Cr release assay at the indicated effector/target (E/T) ratio. T2-A24 cells were pulsed with HIV-env peptide (HIV+), SYT-SSX-derived peptide (K9I+), survivin-2B80-88 peptide (2B+), or survivin-C58 peptide (C+), serving as target cells. P(-) indicates T2-A24 target cells without peptide pulsation. K562 target cells were used for monitoring natural killer activity and lymphokine-activated non-specific cytotoxicity.